NetScientific PLC Vortex Biosciences appoints Chairman of SAB
14 Junho 2016 - 3:01AM
RNS Non-Regulatory
TIDMNSCI
NetScientific PLC
14 June 2016
("NetScientific" or the "Company" or the "Group")
Vortex Biosciences appoints Dr. Massimo Cristofanilli as
Chairman of newly formed Scientific Advisory Board
London, UK - 14 June 2016 - NetScientific plc ("NetScientific",
AIM:NSCI), the transatlantic biomedical and healthcare technology
group, notes its portfolio company Vortex Biosciences has appointed
Dr. Massimo Cristofanilli as Chairman of its newly formed
Scientific Advisory Board.
Commenting on the appointment, NetScientific's Chief Executive
Officer, Francois R. Martelet, said: "Vortex Biosciences is at a
pivotal point as its circulating tumour cell enrichment system, the
VTX-1, moves towards commercialisation. The appointment of Dr.
Cristofanilli, who will be joining to spearhead the creation of
Vortex's world class Scientific Advisory Board, will help underpin
their clinical strategy as the company moves through this
transformational period."
Vortex Bioscience's press release follows:
Vortex Biosciences Appoints Dr. Massimo Cristofanilli As
Chairman of Newly Formed Scientific Advisory Board
Leading Expert on Liquid Biopsies to Provide Perspective on
Research and Development of Next Generation Circulating Tumor Cell
Enrichment System
MENLO PARK, CA, June 14th - Vortex Biosciences, provider of
circulating tumor cell (CTC) enrichment systems, today announced
the appointment of Dr. Massimo Cristofanilli as the Chairman of its
newly formed Scientific Advisory Board (SAB). The SAB's mission
will be to provide valuable scientific and clinical insights, along
with strategic guidance in decision-making to support the
development and commercialization of Vortex's CTC enrichment system
for both the research and diagnostic markets.
"Dr. Cristofanilli brings deep expertise in the clinical
application of liquid biopsies," said Gene Walther, Chief Executive
Officer of Vortex Biosciences. "We are excited he is willing to
chair our scientific advisory board and help us execute our
clinical strategy as we commercialize our next generation CTC
enrichment system, the VTX-1."
Massimo Cristofanilli, MD, an expert in the translational
research and treatment of patients with inflammatory breast cancer
(IBC), is Professor of Medicine in the Division of
Hematology/Oncology at Northwestern University Feinberg School of
Medicine and Director of Lurie Cancer Center OncoSET. Dr.
Cristofanilli has led the development of novel diagnostic and
prognostic markers in primary and metastatic breast cancer. His
research is focused on advancing a patient-centered, biology driven
model of cancer care; combining sophisticated tissue and
blood-based molecular diagnostic technologies and innovative
treatments. Prior to joining the Lurie Cancer Center, Dr.
Cristofanilli was Director of the Breast Care Center and Deputy
Director for Translational Research at the Sidney Kimmel Cancer
Center at Thomas Jefferson University. He previously served as
Chair of the Department of Medical Oncology at Fox Chase Cancer
Center, and Executive Director of the Morgan Welch Inflammatory
Breast Cancer Program and Clinic at the University of Texas MD
Anderson Cancer Center.
About Vortex Biosciences
Vortex Biosciences is a cancer research and diagnostics company
that integrates cancer biology, microfluidic engineering and
informatics to develop tools for isolating and characterizing
circulating tumor cells. The Vortex VTX-1 instrument harvests
intact circulating tumor cells from whole blood samples for use in
downstream research and clinical applications such as patient
stratification in clinical trials, monitoring disease progression
and drug treatment effectiveness. With a mission to enable
noninvasive diagnosis of cancer and real-time monitoring throughout
a patient's treatment, Vortex is at the forefront of accelerating
cancer research and improving patient outcomes. Vortex is a core
subsidiary of NetScientific plc, a transatlantic healthcare
technology group with an investment strategy focused on sourcing,
funding and commercializing technologies that significantly improve
the health and well-being of people with chronic diseases. For more
information, visit www.vortexbiosciences.com.
# # #
- Ends -
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet,
M.D., CEO
Ian Postlethwaite, CFO
Consilium Strategic Tel: +44 (0)20 3709 5700
Communications netscientific@consilium-comms.com
Mary-Jane Elliott /
Chris Gardner / Jessica
Hodgson / Chris Welsh
/ Laura Thornton
About NetScientific Plc
NetScientific is a biomedical and healthcare technology group
that funds and develops technologies that offer transformative
benefits to people's lives and society through improved diagnosis,
prognosis and treatment. For more information, please visit the
website at www.netscientific.net.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFJMBTMBTBTTF
(END) Dow Jones Newswires
June 14, 2016 02:01 ET (06:01 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024